Over 40,000 new gut microbes discovered in African populations

Fasenra generated $1.55bn last year, according to AstraZeneca’s financials. Image credit: Alexanderstock23 / Shutterstock. AstraZeneca‘s Fasenra (bevacizumab) is set to challenge GSK’s Nucala (mepolizumab) in

A 59-year-old woman with a background of HIV living with an uncontrollable movement disorder presented to Eoghan Donlon, MB, BCh BAO, MRCPI, of the Mater

Micrograph of malignant mesothelioma. Credit: Nephron/ commons.wikimedia.org. Avenge Bio has obtained orphan drug designation from the US Food and Drug Administration (FDA) for its AVB-001